A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors

Annals of Oncology

Volumn 13, Issue 5, 2002, Pages 755-759

  Mayer, F ^a   Hartmann, J T ^a   von Pawel, J ^b   Beck, J ^c   Schroeder, M ^d   Boehlke, I ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ST JOHANNES HOSPITAL   (Germany)

Author keywords

Dose escalation; Paclitaxel; Phase I study; Phase I II; Solid tumors; UFT

Indexed keywords

ANTINEOPLASTIC AGENT; FOLINIC ACID; PACLITAXEL; TEGAFUR; UFT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME; ADVANCED CANCER; ANEMIA; BLADDER CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG INFUSION; DRUG TOLERANCE; FATIGUE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTICENTER STUDY; NEUROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; SOLID TUMOR; THYROID CARCINOMA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME; COMPARATIVE STUDY; HUMAN; MIDDLE AGE;

EID: 0035985297     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf129     Document Type: Article

References (26)

1. Pharmacokinetics of ftorafur after intravenous and oral administration
2. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients
3. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver
4. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy
5. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma
6. Determination of 5-fluorouracil levels in tumors, blood, and other tissues
7. Effect of co-administration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetra-hydrofuryl)-5-fluorouracil
8. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil
9. Phase I study of UFT (uracil plus futraful preparation)
10. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: Demonstration of schedule-dependent toxicities
11. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer
12. Randomized comparative study of ORZEL (oral uracil/tegafur [UFT] plus leucovorin [LV]) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
13. Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: A phase II study
14. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leukovorin (LV) in patients with metastatic colorectal cancer
15. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin
16. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma
17. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced non-small-cell lung carcinoma: A multi-institutional phase II trial
18. Uracil-tegafur in gastric carcinoma: A comprehensive review
19. Clinical trials on UFT in the treatment of head and neck cancer
20. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas
21. Phase II study of patients with metastatic non-small-cell carcinoma of the lung treated with paclitaxel by 3-hour infusion
22. Recent strategies for the use of paclitaxel in the treatment of urological malignancies
23. Paclitaxel via 1-hour infusion: Clinical experience
24. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
25. Phase I trial of uraciltegafur (UFT) plus oral leucovorin: 28-day schedule
26. Phase I and pharmacokinetic study on the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies